Drug Interactions between cyclophosphamide and Metoprolol Succinate ER
This report displays the potential drug interactions for the following 2 drugs:
- cyclophosphamide
- Metoprolol Succinate ER (metoprolol)
Interactions between your drugs
No interactions were found between cyclophosphamide and Metoprolol Succinate ER. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
cyclophosphamide
A total of 380 drugs are known to interact with cyclophosphamide.
- Cyclophosphamide is in the drug class alkylating agents.
-
Cyclophosphamide is used to treat the following conditions:
- Acute Lymphocytic Leukemia
- Acute Nonlymphocytic Leukemia
- Bladder Cancer (off-label)
- Brain Tumor (off-label)
- Breast Cancer
- Bullous Pemphigoid (off-label)
- Cancer
- Cervical Cancer (off-label)
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Cogan's Syndrome (off-label)
- Dermatomyositis (off-label)
- Diffuse Large B-Cell Lymphoma
- Endometrial Cancer (off-label)
- Ewing's Sarcoma (off-label)
- Granulomatosis with Polyangiitis (off-label)
- Histiocytosis (off-label)
- Hodgkin's Lymphoma
- Lupus (off-label)
- Lupus Nephritis (off-label)
- Mantle Cell Lymphoma
- Multiple Myeloma
- Multiple Sclerosis (off-label)
- Mycosis Fungoides (off-label)
- Nephrotic Syndrome
- Neuroblastoma (off-label)
- Non Small Cell Lung Cancer (off-label)
- Non-Hodgkin's Lymphoma
- Organ Transplant, Rejection Prophylaxis (off-label)
- Osteosarcoma (off-label)
- Ovarian Cancer
- Pemphigoid (off-label)
- Pemphigus (off-label)
- Primary Immunoglobulin A Nephropathy
- Prostate Cancer (off-label)
- Rheumatoid Arthritis (off-label)
- Scleroderma (off-label)
- Small Cell Lung Cancer (off-label)
- Systemic Sclerosis (off-label)
- Testicular Cancer (off-label)
- Wilms' Tumor (off-label)
Metoprolol Succinate ER
A total of 512 drugs are known to interact with Metoprolol Succinate ER.
- Metoprolol succinate er is in the drug class cardioselective beta blockers.
- Metoprolol succinate er is used to treat the following conditions:
Drug and food interactions
metoprolol food
Applies to: Metoprolol Succinate ER (metoprolol)
ADJUST DOSING INTERVAL: The bioavailability of metoprolol may be enhanced by food.
MANAGEMENT: Patients may be instructed to take metoprolol at the same time each day, preferably with or immediately following meals.
References
- (2001) "Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals
- Darcy PF (1995) "Nutrient-drug interactions." Adverse Drug React Toxicol Rev, 14, p. 233-54
metoprolol food
Applies to: Metoprolol Succinate ER (metoprolol)
ADJUST DOSING INTERVAL: Concurrent administration with calcium salts may decrease the oral bioavailability of atenolol and possibly other beta-blockers. The exact mechanism of interaction is unknown. In six healthy subjects, calcium 500 mg (as lactate, carbonate, and gluconate) reduced the mean peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) of atenolol (100 mg) by 51% and 32%, respectively. The elimination half-life increased by 44%. Twelve hours after the combination, beta-blocking activity (as indicated by inhibition of exercise tachycardia) was reduced compared to that with atenolol alone. However, during a 4-week treatment in six hypertensive patients, there was no difference in blood pressure values between treatments. The investigators suggest that prolongation of the elimination half-life induced by calcium coadministration may have led to atenolol cumulation during long-term dosing, which compensated for the reduced bioavailability.
MANAGEMENT: It may help to separate the administration times of beta-blockers and calcium products by at least 2 hours. Patients should be monitored for potentially diminished beta-blocking effects following the addition of calcium therapy.
References
- Kirch W, Schafer-Korting M, Axthelm T, Kohler H, Mutschler E (1981) "Interaction of atenolol with furosemide and calcium and aluminum salts." Clin Pharmacol Ther, 30, p. 429-35
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.